Data Integrity—A Study of Current Regulatory Thinking and Action

References

1. 1.↵
   1. Cosgrove T.

   Opening Remarks. Presented at the ISPE-FDA CGMP Conference, Baltimore, MD, USA, June 2–4, 2014.
2. 2.↵
   FDA Media Briefing. Commissioner Hamburg on her visit to India. http://www.fda.gov/downloads/NewsEvents/Newsroom/MediaTranscripts/UCM387679.pdf (accessed January 24, 2015).
3. 3.↵
   Business Today. Compliance doesn't end with approval: US FDA commissioner. http://businesstoday.intoday.in/storyprint/203213 (accessed January 24, 2015).
4. 4.↵
   1. Moore N,
   2. Juillet Y,
   3. Bertoye P.-H.

   Intégrité des données scientifiques: transparence des données recueillies au cours des essais cliniques, accès aux données. Thérapie 2007, 62(3), 203–209.

   OpenUrlPubMed
5. 5.↵
   1. Lindblad A. S.,
   2. Manukyan Z.,
   3. Purohit-Sheth T.,
   4. Gensler G.,
   5. Okwesili P.,
   6. Meeker-O'Connell A.,
   7. Ball L.,
   8. Marler J. R.

   Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection. Clinical Trials. 2014, 11(2), 205–217.

   OpenUrlPubMed
6. 6.↵
   1. Takahashi K.

   Data Integrity: Warning Letters. Presented at the PDA Annual Meeting, San Antonio, TX, USA, April 7–9, 2014.
7. 7.↵
   GCP Inspectors Working Group. Reflection Paper on Expectations for Electronic Source Data and Data Transcribed to Electronic Data Collection Tools in Clinical Trials; EMA/INS/GCP/454280/2010: London, UK, June 9, 2010.
8. 8.↵
   1. Katz P. R.

   Protecting the public's health through the application integrity policy. Food & Drug Law Journal 2010, 65(3), 539–543.

   OpenUrlPubMed
9. 9.↵
   1. Rosa C.

   Current Inspectional & Compliance Issues in Data Integrity. Presented at the ISPE-FDA CGMP Conference, Baltimore, MMD, USA, June 2–4, 2014.
10. 10.↵
    1. Rosa C.

    ICH Q7 Principles and Data Integrity. Presented at the PDA-PIC/S Training on ICH Q7, Bethesda, MD, USA, February 2014.
11. 11.↵
    MHRA News. MHRA expectation regarding self-inspection and data integrity. http://webarchive.nationalarchives.gov.uk/20141205150130/ http://www.mhra.gov.uk/Howweregulate/Medicines/Inspectionandstandards/GoodManufacturingPractice/News/CON355490 (accessed January 24, 2015).
12. 12.↵
    FDA. Guidance for Industry. Electronic Source Data in Clinical Investigations; FDA: Silver Spring, MD, USA, 2013.
13. 13.↵
    FDA Inspection Guides. Glossary of Computer System Software Development Terminology. http://www.fda.gov/iceci/inspections/inspectionguides/ucm074875.htm (accessed January 24, 2015).
14. 14.↵
    FDA. Guidance for Industry. Part 11, Electronic Records; Electronic Signatures—Scope and Application; FDA: Silver Spring, MD, USA, 2003.
15. 15.↵
    1. Hickey C.

    FDA works with China to ensure medical-product safety. FDA Voice. http://blogs.fda.gov/fdavoice/index.php/2014/04/fda-works-with-china-to-ensure-medical-product-safety/ (accessed January 24, 2015).
16. 16.↵
    EMA. Roadmap to 2015: EMA Contribution to Science, Medicines and Health; London, UK, 2010.
17. 17.↵
    EMA. EU GMPs. Medicinal Products for Human and Veterinary Use: Annex 11 Computerised Systems. SANCO/C8/AM/sl/ares(2010)1064599; Brussels, Belgium, 2011.
18. 18.↵
    FDA. Guidance for Industry. Oversight of Clinical Investigations—A Risk-Based Approach to Monitoring; FDA: Silver Spring, MD, USA, 2013.
19. 19.↵
    FDA. Guidance for Industry. Product Development under the Animal Rule—Draft; FDA: Silver Spring, MD, USA, 2014.
20. 20.↵
    Press Release: PIC/S Expert Circle on Active Pharmaceutical Ingredients (APIs); Rome, Italy; http://www.picscheme.org/bo/commun/upload/document/press-release-rome-2014-copy1.pdf (accessed January 24, 2015).